van Ruiten, Charlotte C.
Smits, Mark M.
Kok, Megan D.
Serné, Erik H.
van Raalte, Daniël H.
Kramer, Mark H. H.
Nieuwdorp, Max
IJzerman, Richard G.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial
https://doi.org/10.1186/s12933-022-01492-x
Article History
Received: 24 December 2021
Accepted: 8 March 2022
First Online: 28 April 2022
Declarations
:
: The study protocol, protocol amendments, and any other protocol-specific documents were reviewed and approved by local authorities and the ethics review board of the Amsterdam University Medical Center, location VUmc. The study complied with the Declaration of Helsinki and Good Clinical Practice guidelines and was registered at the ClinicalTrials.gov (NCT03361098).
: Not applicable.
: R.G.IJ. is principal investigator of studies sponsored by research grants from AstraZeneca, Eli Lilly & Co., and Novo Nordisk. Trough M.H.H.K., the Amsterdam University Medical Centers, location VUmc, received research grants from AstraZeneca, Boehringer Ingelheim, Novo Nordisk and Sanofi-Aventis. D.H.v.R. serves on advisory boards of Boehringer Ingelheim, Eli Lilly Alliance, Novo Nordisk, Sanofi, and Merck Sharp & Dohme (MSD), and received research grants from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Sanofi, and MSD. M.N. is supported by apersonal ZONMW VICI Grant 2020 (09150182010020) and received an unrestricted grant from AstraZeneca and serves on the Scientific Advisory Board of Caelus Pharmaceuticals, the Netherlands, and Kaleido, USA. All authors declare they have not received any fees personally in connection with the roles described above, as all honoraria were paid to their employer (Amsterdam University Medical Centers, location VUmc). None of these potential conflicts of interest are relevant to the current article. C.C.v.R., M.M.S., M.K., and E.H.S have no conflict of interest.